This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Evaluation
  • Claim Credit
Ask the Experts: Exploring Newer Treatments and Challenges in Type 2 Diabetes

Ask the Experts: Exploring Newer Treatments and Challenges in Type 2 Diabetes

Format

Slide Lecture Series

Time to Complete

1 hour

Released

May 6, 2019

Expires

May 31, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Pharmacy Credits

Pharmacists may earn 1.00 CPE Credit (0.10 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on ASHP.org and will not be included in your myCME CME History.

Accredited Provider



This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck.

Program Description

This educational activity explores newer treatments and their role in diabetes therapy, including cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 agonists. The faculty address key issues and provide practice pearls for physicians and pharmacists. The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, nurse practitioners, and physician assistants caring for patients with type 2 diabetes mellitus.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Review the safety and efficacy of SGLT-2 inhibitors, including recent cardiovascular outcomes trials.
  • Compare the various formulations of GLP-1 agonists and their place in type 2 diabetes (T2DM) therapy.
  • Discuss the relationship between Non-alcoholic Fatty Liver Disease (NAFLD) and T2DM, including current guidelines.
  • Using patient scenarios, apply these concepts to provide interprofessional care to patients with T2DM.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.

Faculty

Curtis L. Triplitt, PharmD, CDE
Clinical Associate Professor
Medicine/Diabetes
University of Texas Health Science Center at San Antonio
Associate Director
Diabetes Research Unit
Texas Diabetes Institute, University Health System
San Antonio, Texas

Dr. Triplitt discloses the following:
Speakers Bureau: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Janssen
Consultant: Merck

Eric L. Johnson, MD
Associate Professor, Department of Family and Community Medicine
University of North Dakota School of Medicine and Health Sciences
Assistant Medical Director, Altru Diabetes Center
Altru Health System
Grand Forks, North Dakota

Dr. Johnson discloses the following:
Speakers Bureau: Medtronic; Novo Nordisk
Advisory Board: Novo Nordisk; Sanofi

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Instructions

In order to receive credit, participants must complete the pre-assessment questions, post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact elearning@ashp.org.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue